English Українська
  • Main
  • Useful links
  • Information for Contributors
  • About
  • Editorial board

    •
    Article
    World of Medicine and Biology / №4(90), 2024 / CHEMOTHERAPY-INDUCED CARDIAC TOXICITY AND HEART FAILURE
    S. R. Bayramzade, N. I. Mehdiyeva, M. M. Bakhshiyev

    CHEMOTHERAPY-INDUCED CARDIAC TOXICITY AND HEART FAILURE

    About the author: S. R. Bayramzade, N. I. Mehdiyeva, M. M. Bakhshiyev
    Heading REVIEWS
    Type of article Scentific article
    Annotation Over the past 20 years, advancements in cancer treatments have contributed to a consistent decline in cancer-related mortality, paralleled by an increase in cancer survivorship. As survivorship rises, treatment-related side effects, particularly cardiovascular toxicities associated with cancer therapies, have gained prominence due to their significant impact on patient outcomes. Effective management of cardiovascular toxicities is critical, as it influences the choice of anticancer therapies and affects long-term morbidity and mortality among cancer patients. Despite significant advancements in anti-cancer therapies that have improved patient survival, these treatments are often accompanied by an increased risk of treatment-related morbidity and mortality, particularly from cardiovascular diseases. Cardio-oncology, the multidisciplinary field, has gained considerable attention in recent years. However, further research is required to explore the complex mechanisms of chemotherapy-induced cardiovascular toxicity. This review includes recent information and evidence related to assessing the cardiotoxicity of chemotherapy and the ways of managing this problem.
    Tags chemotherapy,cardiotoxicity,myocardial dysfunction
    Bibliography
    • Abdul-Rahman T, Dunham A, Huang H, Bukhari SMA, Mehta A, Awuah WA, et al; American College of Cardiology Medical Student Member Community (ACC:MSMC) – Cardiovascular Research Initiative (CVRI) group. Chemotherapy Induced Cardiotoxicity: A State of the Art Review on General Mechanisms, Prevention, Treatment and Recent Advances in Novel Therapeutics. Curr Probl Cardiol. 2023 Apr;48(4):101591. doi: 10.1016/j.cpcardiol.2023.101591.
    • Alexandre J, Cautela J, Ederhy S, Damaj GL, Salem JE, Barlesi F, et al. Cardiovascular Toxicity Related to Cancer Treatment: A Pragmatic Approach to the American and European Cardio-Oncology Guidelines. J Am Heart Assoc. 2020 Sep 15;9(18):e018403. doi: 10.1161/JAHA.120.018403.
    • Beavers CJ, Rodgers JE, Bagnola AJ, Beckie TM, Campia U, Di Palo KE, et al; American Heart Association Clinical Pharmacology Committee and Cardio-Oncology Committee of the Council on Clinical Cardiology and Council on Genomic and Precision Medicine; and the Council on Peripheral Vascular Disease. Cardio-Oncology Drug Interactions: A Scientific Statement From the American Heart Association. Circulation. 2022 Apr 12;145(15):811–838. doi: 10.1161/CIR.0000000000001056.
    • Brown SA, Ray JC and Herrmann J. Precision cardio-oncology: a systems-based perspective on cardiotoxicity of tyrosine kinase inhibitors and immune checkpoint inhibitors. J. Cardiovasc. Transl. Res 2020; 13, 402–416, 10.1007/s12265-020-09992-5.
    • Bychowski J, Sobiczewski W. Current perspectives of cardio-oncology: Epidemiology, adverse effects, pre-treatment screening and prevention strategies. Cancer Med. 2023 Jul;12(13):14545–14555. doi: 10.1002/cam4.5980.
    • Chaganti BT, Negishi K, Okajima K. Role of Myocardial Strain Imaging in Cancer Therapy-Related Cardiac Dysfunction. Curr Cardiol Rep. 2022 Jun;24(6):739–748. doi: 10.1007/s11886-022-01692-7.
    • Couch LS, Lyon AR, López-Fernández T. Cardio-oncology: a new field requiring guidance. Eur Heart J Cardiovasc Imaging. 2023 Feb 17;24(3): 47. doi: 10.1093/ehjci/jeac250.
    • Curigliano G, Lenihan D, Fradley M, Ganatra S, Barac A, Blaes A, et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol 2020; 31:171–190.
    • Dent SF, Morse A, Burnette S, Guha A, Moore H. Cardiovascular toxicity of novel HER2-targeted therapies in the treatment of breast cancer. Curr Oncol Rep. 2021; 23:128. doi: 10.1007/s11912-021-01114-x.
    • Fanola CL, Ruff CT, Murphy SA, Jin J, Duggal A, Babilonia NA et al. Efficacy and safety of edoxaban in patients with active malignancy and atrial fibrillation: analysis of the ENGAGE AF – TIMI 48 trial. J. Am. Heart Assoc. 2018. 7, e008987, 10.1161/JAHA.118.008987.
    • Gioffré S, Chiesa M, Cardinale DM, Ricci V, Vavassori C, Cipolla CM, et al. Circulating microRNAs as potential predictors of anthracycline-induced troponin elevation in breast cancer patients: diverging effects of doxorubicin and epirubicin. J Clin Med 2020; 9:1418.
    • Harries I, Liang K, Williams M, Berlot B, Biglino G, Lancellotti P, et al. Magnetic Resonance Imaging to Detect Cardiovascular Effects of Cancer Therapy: JACC CardioOncology State-of-the-Art Review. JACC CardioOncol. 2020 Jun 16;2(2):270–292. doi:  0.1016/j.jaccao.2020.04.011.
    • Hauwanga WN, McBenedict B, Amadi ES, Dohadwala TK, Johnny C, Asaju F, et al. A Systematic Review of the Cardiotoxic Effects of Targeted Therapies in Oncology. Cureus. 2024 Aug 6;16(8):e66258. doi: 10.7759/cureus.66258.
    • Kamaraju S, Mohan M, Zaharova S, Wallace B, McGraw J, Lokken J, et al. Interactions between cardiology and oncology drugs in precision cardio-oncology. Clin Sci (Lond). 2021 Jun 11;135(11):1333–1351. doi: 10.1042/CS20200309.
    • Kersten J, Fink V, Kersten M, May L, Nunn S, Tadic M, et al. CMR reveals myocardial damage from cardiotoxic oncologic therapies in breast cancer patients. Int J Cardiovasc Imaging. 2024 Feb;40(2):225-235. doi: 10.1007/s10554-023-02996-7.
    • Laksono S, Yuniadi Y, Soesanto AM, Raharjo SB, Lisnawati, Bardosono S, et al. Comparison of Global Longitudinal Strain in Dual-chamber versus Ventricular Pacemaker in Complete Heart Block. J Cardiovasc Echogr. 2024 Jan-Mar;34(1):14–18. doi:  10.4103/jcecho.jcecho_78_23.
    • Lancellotti P, Suter TM, López-Fernández T, Galderisi M, Lyon AR, Van Der Meer P, et al. Cardio-oncology services: rationale, organization, and implementation. Eur Heart J 2019; 40:1756–1763.
    • López‐Fernández T, Martín‐García A, Roldán Rabadán I, Mitroi C, Mazón Ramos P, Díez‐Villanueva P, et al. Atrial fibrillation in active cancer patients: expert position paper and recommendations. Rev Esp Cardiol (Engl Ed). 2019; 72:749–759. 
    • Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al; ESC Scientific Document Group. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022 Nov 1;43(41):4229–4361. doi: 10.1093/eurheartj/ehac244.
    • Madanat L, Gupta R, Weber P, Kumar N, Chandra R, Ahaneku H, et al. Cardiotoxicity of Biological Therapies in Cancer Patients: An In-depth Review. Curr Cardiol Rev. 2023; 19(3):e310522205428. doi: 10.2174/1573403X18666220531094800.
    • Mesitskaya DF, Zaki ZAF, Poltavskaya MG, Andreev DA, Levshina AR, Sultygova EA, et al. A single-lead ECG based cardiotoxicity detection in patients on polychemotherapy, IJC Heart & Vasculature, Volume 50, 2024, 101336, ISSN 2352–9067. https://doi.org/10.1016/j.ijcha.2024.101336.
    • Muresan L, Cismaru G, Martins RP, Bataglia A, Rosu R, Puiu M, et al. Recommendations for the use of electrophysiological study: Update 2018. Hellenic J Cardiol. 2019 Mar-Apr;60(2):82–100. doi: 10.1016/j.hjc.2018.09.002.
    • Negishi T, Miyazaki S, Negishi K. Echocardiography and Cardio-Oncology. Heart Lung Circ. 2019 Sep;28(9):1331–1338. doi: 10.1016/j.hlc.2019.04.023.
    • Nolan MT, Creati L, Koczwara B, Kritharides L, Lynam J, Lyon AR, et al. First European Society of Cardiology Cardio-Oncology Guidelines: A Big Leap Forward for an Emerging Specialty. Heart Lung Circ. 2022 Dec;31(12):1563–1567. doi:  10.1016/j.hlc.2022.11.003.
    • Salem J-E, Nguyen LS, Moslehi JJ, Ederhy S, Lebrun-Vignes B, Roden DM, et al. Anticancer drug-induced life-threatening ventricular arrhythmias: a World Health Organization pharmacovigilance study. Eur Heart J 2021; 42:3915–3928.
    • Shaaban NH, Abayazeed RM, Sobhy MA, Elsharkawy EM, Hammad BA. Role of Global Left Ventricle Longitudinal Strain and Cardiac Biomarkers in the Early Detection of Cancer Therapy-Related Dysfunction in Patients Treated with Cardiotoxic Chemotherapeutic Drugs in a Cardio-Oncology Clinic. Cureus. 2024 Oct 18;16(10): 71766. doi: 10.7759/cureus.71766.
    • Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024 Jan-Feb;74(1):12–49. doi:  10.3322/caac.21820.
    • Skrypnyk IM, Maslova GS, Lymanets TV. Overweight and obesity as risk factors for chemotherapy-induced hepatotoxicity in patients with acute lymphoblastic leukemia. World of medicine and biology. 2022; 2 (80): 146–150. doi: 10.26724/2079-8334-2022-2-80-146-150.
    • Spînu Ș, Cismaru G, Boarescu PM, Istratoaie S, Negru AG, Lazea C, et al. ECG Markers of Cardiovascular Toxicity in Adult and Pediatric Cancer Treatment. Dis Markers. 2021 Jan 19; 2021:6653971. doi: 10.1155/2021/6653971.
    • Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71:209–249.
    • Tandia M, Abbara C, Noel-Hudson M-S, Amor D, Polrot M, Gonin P et al. Bevacizumab and sorafenib modulate p-glycoprotein function in vitro and bevacizumab increases in vivo sorafenib plasma concentrations in mice. Int. J. Innov. Res. Med. Sci 2020; 5, 261–267, 10.23958/ijirms/vol05-i08/396.
    • Teske AJ. The ESC cardio-oncology 2022 guidelines; the ball is in our court. Eur Heart J Cardiovasc Imaging. 2023 Feb 17;24(3):45–46. doi: 10.1093/ehjci/jeac219.
    • Venneri L, Zoppellaro G, Khattar RS. Cardio-oncology: the role of advanced echocardiography in cancer patients. Expert Rev Cardiovasc Ther. 2019 Apr;16(4):249–258. doi: 10.1080/14779072.2018.1443394.
    • Watanabe M, Yakushijin K, Tanaka H, Chijiki R, Saeki M, Hirakawa Y, et al. Global longitudinal strain is superior to ejection fraction for long-term follow-up after allogeneic hematopoietic stem cell transplantation. EJHaem. 2022 Nov 7;4(1):192–198. doi:  10.1002/jha2.586.
    • Zhang L, Awadalla M, Mahmood SS, Nohria A, Hassan MZ, Thuny F, et al. Cardiovascular magnetic resonance in immune checkpoint inhibitor‐associated myocarditis. Eur Heart J. 2020;41:1733–1743.
    • Zhang X, Sun Y, Zhang Y, Fang F, Liu J, Xia Y, et al. Cardiac Biomarkers for the Detection and Management of Cancer Therapy-Related Cardiovascular Toxicity. J Cardiovasc Dev Dis. 2022 Oct 29;9(11):372. doi: 10.3390/jcdd9110372.
    Publication of the article «World of Medicine and Biology» №4(90), 2024 year, 229-235 pages, index UDK 616-006-06:615.277.3
    DOI 10.26724/2079-8334-2024-4-90-229-235